Exercise and GLP-1 drugs team up to transform heart health, study reveals

A new study published in Nature Metabolism in 2026 highlights the combined benefits of exercise and GLP-1 receptor agonists (GLP-1RAs) on heart health. Researchers Jordan and McDermott found that both interventions work together to improve cardiovascular outcomes beyond traditional measures like weight loss. The study shows that GLP-1 receptor activation enhances heart rate variability and balances the sympathetic and parasympathetic nervous systems. This reduces the risk of irregular heartbeats and sudden cardiac death. Exercise also boosts GLP-1 receptor levels in heart tissue, strengthening the effects of GLP-1RAs and creating a beneficial cycle for metabolic health.

GLP-1RAs improve blood vessel function by increasing nitric oxide availability, which widens arteries and reduces stiffness. They also lower oxidative stress and inflammation in the cardiovascular system. These effects occur independently of weight changes, offering direct protection to the heart muscle.

Under stress conditions like reduced blood flow, GLP-1 receptor signalling helps the heart use energy more efficiently. This limits damage during a heart attack and supports recovery afterwards. Exercise provides similar benefits, aiding cardiac repair after injury.

The combined use of exercise and GLP-1RAs further reduces systemic inflammation. This could slow the buildup of plaque in arteries and stabilise existing deposits. The researchers suggest future clinical trials should measure broader outcomes, such as blood vessel function, inflammation levels, and heart metabolism, rather than focusing only on weight loss. The findings suggest that GLP-1RAs and exercise together offer significant cardiovascular benefits. These include better blood flow, reduced inflammation, and improved heart recovery. Future studies will need to explore ways to improve long-term adherence to these treatments, possibly through new drug formulations or digital health tools.